Antiplatelet and Anticoagulation Therapies

radial access, transradial access trial using anticoagulants
News | Radial Access | June 15, 2017

June 15, 2017 — In patients undergoing ...

Cost comparison between NOACs, novel oral anticoagulants
News | Antiplatelet and Anticoagulation Therapies | May 31, 2017

May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare...

anticoagulants increase dementia risks
Feature | Antiplatelet and Anticoagulation Therapies | May 12, 2017

May 12, 2017 – A new study found that dementia rates increase with delays in starting anticoagulation treatment for...

Siemens Xprecia Stride anticoagulation, coagulation PT/INR or INR testing at the point of care (POC)

Point-of-care coagulation PT/INR testing with handheld devices can help improve outcomes with more convenient and frequent measurements to keep patients within the therapeutic range of anticoagulant agents.

Feature | Point of Care Testing | May 05, 2017 | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios

Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on...

Ablation procedure, EP lab, Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation
Feature | Atrial Fibrillation | March 29, 2017

March 29, 2017 — Uninterrupted treatment with dabigatran (Pradaxa), a non-vitamin K,...

bleeding complications, rivaroxaban, antiplatelet therapy, post-ACS, acute coronary syndrome, ACC.17 study
News | Antiplatelet and Anticoagulation Therapies | March 23, 2017

March 23, 2017 — Bleeding complications did not increase for patients with acute coronary syndrome treated with...

rivaroxaban, asprin, venous thromboembolism, VTE recurrence, clinical study, ACC.17
News | Antiplatelet and Anticoagulation Therapies | March 23, 2017

March 23, 2017 — In patients at elevated risk for a recurrence of potentially life- threatening blood clots, a low...

RESOLVE study, RESOLVE trial, subclinical leaflet thrombosis

A CT study from the RESOLVE Trial showing valve leaflet thrombosis on a TAVR device. The trial examined a range of surgical and transcatheter valves to show thrombosis is found across both types of devices. It also examined if anticoagulation or antiplatelet therapy could reduce thrombosis and allow a greater range of leaflet motion.

Feature | Heart Valve Technology | March 21, 2017

March 21, 2017 — About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood...

warfarin, anticoagulation therapy, atrial fibrillation patients, Duke Clinical Research Institute study, stroke
News | Antiplatelet and Anticoagulation Therapies | March 14, 2017

March 14, 2017 — More than 80 percent of stroke patients with a history of...

CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017

March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc. first-in-class Cobra...

Xarelto, rivaroxaban, COMPASS study, ends early,
News | Antiplatelet and Anticoagulation Therapies | February 09, 2017

February 9, 2017 — Janssen Research & Development LLC (Janssen) announced that the Phase 3 COMPASS trial is...

The Xprecia Stride Coagulation Analyzer delivers fast, reliable prothrombin time/international normalized ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist. It is the latest INR testing system to enter the market in late 2016. Read the article “Siemens Receives FDA Clearance of Xprecia Stride Coagulation Analyzer.”
 

 

Feature | Point of Care Testing | December 30, 2016 | Ravi Chawat

Point of care testing devices are gaining widespread approval for prompt medical diagnoses, especially in cardiology...

Overlay Init